Brand-name drug manufacturers in the US use several strategies to delay generic competition,1 including obtaining a thicket of patents to protect beyond a drug’s active ingredient and original use.2 Such patents can cover use of the drug for supplemental indications that the US Food and Drug Administration (FDA) approves after a medication is already on the market.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Walsh BS, Sarpatwari A, Rome BN, Kesselheim AS. Frequency of First Generic Drug Approvals With “Skinny Labels” in the United States. JAMA Intern Med. 2021;181(7):995–997. doi:10.1001/jamainternmed.2021.0484
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: